Dose Escalation Study of Epirubicin and Docetaxel in Patients with Advanced or Recurrent Breast Cancer

Publisher： Karger

E-ISSN： 1421-9794|54|5|379-385

ISSN： 0009-3157

Source： Chemotherapy, Vol.54, Iss.5, 2008-08, pp. : 379-385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Dose Escalation Trial of Biweekly Docetaxel and Gemcitabine with Filgrastim or Pegfilgrastim for the Treatment of Patients with Advanced Solid Tumors

By  

Chemotherapy, Vol. 56, Iss. 2, 2010-04 ,pp. : 135-141

Karger

Access to resources Recommend Favorite

Weekly Paclitaxel in the Treatment of Advanced or Metastatic Breast Cancer Previously Treated or Not Treated with Docetaxel: A Phase II Study

By  

Chemotherapy, Vol. 51, Iss. 2-3, 2005-06 ,pp. : 126-131

Karger

Access to resources Recommend Favorite

Phase I Study of S-1 plus Nedaplatin in Patients with Advanced/Recurrent Head and Neck Cancer

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 453-458

Karger

Access to resources Recommend Favorite

A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients

By  

Chemotherapy, Vol. 58, Iss. 5, 2013-01 ,pp. : 411-418

Karger

Access to resources Recommend Favorite

Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer

By  

Chemotherapy, Vol. 57, Iss. 2, 2011-03 ,pp. : 147-155

Karger

Access to resources Recommend Favorite